

Receipt date: 08/05/2008

Doc code :IDS

Doc description: Information Disclosure Statement (IDS) Filed

10733488 - GAU: 1648

PTO/SB/08a (08-08)

Approved for use through 08/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10733488
Filing Date	2003-12-10
First Named Inventor	Yaron Ilan
Art Unit	1648
Examiner Name	Emily M. Le
Attorney Docket Number	5795-082350

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20040171526	A1	2004-09-02	Ilan et al.	
	2	20070010483	A1	2007-01-11	Ilan et al.	
	3	20040087485	A1	2004-05-06	Ilan et al.	
	4	20040023909	A1	2004-02-05	Roy-Chowdhury et al.	
	5	20040171522	A1	2004-09-02	Ilan et al.	

/E.L./

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Receipt date: 08/05/2008

10733488 - GAU: 1648

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10733488
Filing Date	2003-12-10
First Named Inventor	Yaron Ilan
Art Unit	1648
Examiner Name	Emily M. Le
Attorney Docket Number	5795-082350

6						
7						
8						
9						
10						
11						

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No.	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	9933475	WO	A1	1999-07-08	A & Science Invest AB		<input type="checkbox"/>
	2							<input type="checkbox"/>
	3							<input type="checkbox"/>

/E.L./

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Receipt date: 08/05/2008 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10733488	10733488 - GAU: 1648
	Filing Date		2003-12-10	
	First Named Inventor	Yaron Ilan		
	Art Unit	1648		
	Examiner Name	Emily M. Le		
	Attorney Docket Number	5795-082350		

4								<input type="checkbox"/>
---	--	--	--	--	--	--	--	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	MARGALIT ET AL., "Glucocerebroside Treatment Ameliorates Con-A Hepatitis by Inhibition of NKT Lymphocytes: A New Immunomodulatory Tool," Hepatology, Vol. 38, No. 4, Suppl. 1, page 163A, 2003 (Abstract only)	<input type="checkbox"/>
	2	BLEICHER ET AL., "Expression of murine CD1 on gastrointestinal epithelium," Science, Vol. 250, pages 679-682, November 2, 1990.	<input type="checkbox"/>
	3	COLLINS ET AL., "RAG1, RAG2 and pre-T cell receptor alpha chain expression by adult human hepatic T cells: evidence for extrathymic T cell maturation," Eur. J. Immunol., Vol. 26, pages 3114-3118, 1996.	<input type="checkbox"/>
	4	MADSEN ET AL., "Interleukin 10 prevents cytokine-induced disruption of T84 monolayer barrier integrity and limits chloride secretion," Gastroenterology, Vol. 113, pages 151-159, 1997.	<input type="checkbox"/>
	5	MITCHELL ET AL., "Fatty liver. Chemical shift phase-difference and suppression magnetic resonance imaging techniques in animals, phantoms, and humans," Invest. Radiol., Vol. 26, pages 1041-1052, December 1991.	<input type="checkbox"/>
	6	NAMIMOTO ET AL., "Adrenal Masses: Quantification of Fat Content with Double-Echo Chemical Shift In-Phase and Opposed-Phase FLASH MR Images for Differentiation of Adrenal Adenomas," Radiology, Vol. 218, No. 3, pages 642-646, March 2001.	<input type="checkbox"/>
	7	SULLARDS ET AL., "Structure determination of soybean and wheat glucosylceramides by tandem mass spectrometry," J. Mass Spectrometry, Vol. 35, pages 347-353, 2000.	<input type="checkbox"/>
	8	TROP ET AL., "Liver-Associated Lymphocytes Expressing NK1.1 Are Essential for Oral Immune Tolerance Induction in a Murine Model," Hepatology, Vol. 29, No. 3, pages 746-755, 1999.	<input type="checkbox"/>

/E.L./

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Receipt date: 08/05/2008

Application Number

10733488

10733488 - GAU: 1648

Filing Date

2003-12-10

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

First Named Inventor

Yaron Ilan

Art Unit

1648

Examiner Name

Emily M. Le

Attorney Docket Number

5795-082350

9	VICARI ET AL., "Mouse NK1.1+ T cells: a new family of T cells," Immunology Today, Vol. 17, No. 2, pages 71-76, February 1996.	<input type="checkbox"/>
10	MAKOWSKA ET AL., "Differences in the Ligand Specificity between CD1d-Restricted T Cells with Limited and Diverse T-Cell Receptor Repertoire," Scand. J. Immunol., Vol. 52, pages 71-79, 2000.	<input type="checkbox"/>
11	SMYTH ET AL., "NKT cells - conductors of tumor immunity?" Tumour Immunology, Current Opinion in Immunology, Vol. 14, pages 165-171, 2002.	<input type="checkbox"/>
12	VAN DER VLIET ET AL., "Effects of a-galactosylceramide (KRN7000), interleukin-12 and interleukin-7 on phenotype and cytokine profile of human Va24+ Vb11 T cells," Immunology, Vol. 98, pages 557-563, 1999.	<input type="checkbox"/>
13	HAHN, "Subversion of immune responses by hepatitis C virus: immunomodulatory strategies beyond evasion?" Current Opinion in Immunology, Vol. 15, pages 443-449, 2003.	<input type="checkbox"/>
14	DE FRANCESCO ET AL., "Challenges and successes in developing new therapies for hepatitis C," Nature, Vol. 436, No. 18, pages 953-960, August 2005.	<input type="checkbox"/>
15	LIPPINCOTT ET AL., "The Hepatitis C Viruses," Fields Virology, Fourth Edition, Vol. 1, pages 1004-1016, 2001.	<input type="checkbox"/>
16	MAJOR ET AL., "Hepatitis C Viruses," Fields Virology, Fourth Edition, Vol. 1, pages 1127-1161, 2001.	<input type="checkbox"/>
17	CONNOLLY ET AL., "Preoperative fasting and administration of regular medications in adult patients presenting for elective surgery. Has new evidence changed clinical practice?" European Journal of Anaesthesiology, Vol. 17, pages 219-220, 2000.	<input type="checkbox"/>
18	ZITZMANN ET AL., "Abnormal Glycosylation in Disease and Therapy: Relevance to Chronic Viral Infections," The Glycobiology Institute, Dept. of Biochemistry, Oxford University, Oxford, United Kingdom; Viral Hepatitis Group, Kimmel Cancer Center, Jefferson Medical College, Philadelphia, Pennsylvania, USA, 1999. (Abstract only).	<input type="checkbox"/>
19	MARGALIT ET AL., "Amelioration of Hepatic Fibrosis via B-Glucosylceramide Mediated Immune Modulation is Associated with NKT Lymphocyte Distribution and a Cytokine Shift," American Association for Study of Liver Disease, meeting, November 2005. (Abstract only).	<input type="checkbox"/>

/E.L./

EFS Web 2.1.4

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Receipt date: 08/05/2008

Application Number

10733488

10733488 - GAU: 1648

Filing Date

2003-12-10

First Named Inventor

Yaron Ilan

Art Unit

1648

Examiner Name

Emily M. Le

Attorney Docket Number

5795-082350

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

20	MARGALIT ET AL., "Suppression of Hepatocellular Carcinoma by Glucocerebroside is Associated with Altered NKT and CD8+ Lymphocyte Distributions, Stat1 Expression, Lack of Stat6 Expression, and a Th1-Type Immune Response," American Association for Diseases of the Liver, Boston, MA, October 2004. (Abstract only).	<input type="checkbox"/>
21	ZIGMOND ET AL., "Facilitation of Hepatocellular Carcinoma Growth in Mice by Double Negative NKT Regulatory Lymphocytes, is Inhibited by EX VIVO Exposure to B-Glucosylceramide," American Association for Study of Liver Disease, meeting, November 2005. (Abstract only).	<input type="checkbox"/>
22	AXFORD, "Glycobiology & Medicine: A Millennial Review," GlycoScience, March 30, 2001.	<input type="checkbox"/>
23		<input type="checkbox"/>
24		<input type="checkbox"/>
25		<input type="checkbox"/>
26		<input type="checkbox"/>
27		<input type="checkbox"/>
28		<input type="checkbox"/>
29		<input type="checkbox"/>
30		<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10733488	10733488 - GAU: 1648
	Filing Date		2003-12-10	
	First Named Inventor	Yaron Ilan		
	Art Unit	1648		
	Examiner Name	Emily M. Le		
	Attorney Docket Number	5795-082350		

EXAMINER SIGNATURE			
Examiner Signature	/Emily Le/	Date Considered	10/29/2008
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			
<p><small>¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.</small></p>			